Skip to content

Initial study of the effects of cannabidiol in patients with generalized anxiety compared to the effects of an anxiolytic (clonazepan)

Pilot study of the effects of Cannabidiol in patients with Generalized Anxiety Disorder compared to the effects of Clonazepan

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-2fw8kg
Enrollment
Unknown
Registered
2020-08-07
Start date
2020-08-21
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous system disease

Interventions

Intervention: Cannabidiol, 300mg (two daily 150mg oral doses) (BSPG-Pharm, Sandwich, UK), which will be dissolved in corn oil and packed in gelatin capsules. 15 participants will receive the intervent
Drug

Sponsors

Faculdade de Medicina de Ribeirão Preto - USP
Lead Sponsor
Faculdade de Medicina de Ribeirão Preto - USP
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Generalized Anxiety Disorder (from SCID-5-CV); both sexes, education above eight years; age between 18 and 60 years; total score greater than or equal to 20 on the Hamilton Rating Scale for Anxiety (HAMA); total score greater than or equal to the Global Clinical Impression - Severity scale (CGI-S); total score greater than or equal to 17 on the Hamilton Depression Rating Scale (HAMD17).

Exclusion criteria

Exclusion criteria: Presence of general medical condition; history of neurological disease (except headache); current or past diagnosis of psychoactive substance abuse or use in the past three months; psychotic conditions of any nature according to SCID-5_CV throughout life; other psychiatric diagnoses in addition to generalized anxiety disorder in the last 6 months (except for past remitted depression, social phobia and / or specific phobias); suicide risk (including suicide attempt in the last 1 year); history of previous drug treatment for generalized anxiety disorder; hx of allergy or idiosyncratic reactions to Cannabis sativa derivatives.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1 - decrease in symptoms of anxiety assessed using the Hamilton Anxiety Rating Scale (HAMA) and Generalized Anxiety Disorder Questionnaire (GAD7)

Secondary

MeasureTime frame
Secondary outcome 1 - level of side effects, assessed using the Psychotropic Side Effects Scale of the Clinical Research Committee of the Scandinavian Society for Psychopharmacology (UKU) and the Epworth Sleepiness Scale;Secondary outcome 2 - level of concern, assessed using the Pennsylvania State Concern Questionnaire (PSWQ);Secondary outcome 3 - decrease in facial emotion recognition bias, assessed through a computerized online task, consisting of 24 photo stimuli of actors, strangers, of both sexes, representing expressions of six basic emotions (joy, sadness, fear, disgust, anger and surprise), which must be recognized by the participants.

Countries

Brazil

Contacts

Public ContactFlávia Osório

Faculdade de Medicina de Ribeirão Preto - USP

flaliosorio@gmail.com+55-016-36022530

Outcome results

None listed

Source: REBEC (via WHO ICTRP)